| BTH1677/Bevacizumab/ Carboplatin/Paclitaxel (N = 48) | Bevacizumab/ Carboplatin/Paclitaxel (N = 23) |  | ||
---|---|---|---|---|---|
n (%) | 95% CI | n (%) | 95% CI | P valuef | |
Objective Response Ratea,b | 29 (60.4) | (45.3, 74.2) | 10 (43.5) | (23.2, 65.5) | 0.2096 |
Disease Control Rateb,c | 45 (93.8) | (82.8, 98.7) | 21 (91.3) | (72.0, 98.9) | 0.6563 |
Best Observed Responseb | |||||
 Complete response | 1 (2.1) | (0.1, 11.1) | 0 | NA |  |
 Partial response | 28 (58.3) | (43.2, 72.4) | 10 (43.5) | (23.2, 65.5) | 0.3113 |
 Stable disease | 16 (33.3) | (20.4, 48.4) | 11 (47.8) | (26.8, 69.4) | 0.2992 |
 Progressive disease | 3 (6.3) | (1.3, 17.2) | 2 (8.7) | (1.1, 28.0) | 0.6563 |
Duration of Objective Tumor Responsed | Â | Â | HR (95% CI)g | ||
Patients with objective response (CR + PR) | 29 | 10 |  | ||
Patients (% responding patients) with known duration (uncensored) | 9 (31.0) | 3 (30.0) | Â | ||
Patients (% responding patients) with unknown duration (censored) | 20 (69.0) | 7 (70.0) | Â | ||
Duration of objective response (months) | |||||
 Median (95% CI) | 10.3 (5.6, NE) | 5.6 (1.5, NE) | 0.92 (0.27, 4.20) | ||
 Log-rank P value |  |  | 0.9040 | ||
Progression-Free Survivale | Â | Â | HR (95% CI)g | ||
Patients with PD or died, n (%) | 17 (34.0) | 6 (26.1) | Â | ||
Patients censored, n (%) | 33 (66.0) | 17 (73.9) | Â | ||
Progression-free survival (months) | |||||
 Median (95% CI) | 11.6 (7.0, NE) | 9.6 (7.1, NE) | 1.31 (0.54, 3.65) | ||
 Log-rank P value |  |  | 0.5639 |